OA
MCID: OST012
MIFTS: 78

Osteoarthritis (OA)

Categories: Bone diseases, Muscle diseases

Aliases & Classifications for Osteoarthritis

MalaCards integrated aliases for Osteoarthritis:

Name: Osteoarthritis 12 74 25 29 54 6 42 3 15 37 62 39 17
Osteoarthrosis 12 25 15
Degenerative Joint Disease 12 25
Degenerative Polyarthritis 25 71
Hypertrophic Arthritis 12 25
Arthropathy 25 71
Osteoarthrosis and Allied Disorder 12
Osteoarthritis Deformans 25
Osteoarthrosis Deformans 71
Arthritis, Degenerative 25
Degenerative Arthritis 12
Kashin-Beck Disease 71
Oa 25

Characteristics:


Classifications:



External Ids:

Disease Ontology 12 DOID:8398
ICD9CM 34 715.3
SNOMED-CT via HPO 68 239872002 258211005 263681008
UMLS 71 C0022408 C0029408 C0086743 more

Summaries for Osteoarthritis

Genetics Home Reference : 25 Osteoarthritis is a common disease of the joints that primarily occurs in older adults. This condition is characterized by the breakdown of cartilage, the tough but flexible tissue that covers the ends of the bones at the joints and allows smooth joint movements. One or more parts of the body can be affected, most often the hands, shoulders, spine, knees, or hips. Osteoarthritis usually develops slowly, causing pain, stiffness, and restricted movement as the condition gets worse. Areas of bone no longer cushioned by cartilage rub against each other and start to break down. Further damage is caused as the body attempts to repair and rebuild these tissues. The immune system, which plays a role in healing injuries, targets these areas, and its response leads to inflammation of the joint tissues. Abnormal growths of bone (osteophytes) and other tissue can also occur, and may be visible as enlarged joints. Enlargement of the joints of the fingers is especially noticeable. People with osteoarthritis typically experience stiffness following periods of inactivity such as upon awakening or rising from a chair; the stiffness usually improves as they move around. In some affected individuals, the condition never causes major problems. In others, severe osteoarthritis can impair mobility and the ability to perform daily tasks, affecting quality of life and increasing the risk of other health conditions such as cardiovascular disease. Osteoarthritis is most common in middle age or late adulthood, because the cartilage at the joints naturally begins to thin as people age. However, it can occur earlier in life, especially after injuries affecting the joints such as a type of knee injury called an anterior cruciate ligament (ACL) tear. People who are overweight or whose activities are particularly stressful to the joints are also at increased risk of developing osteoarthritis.

MalaCards based summary : Osteoarthritis, also known as osteoarthrosis, is related to pseudoachondroplasia and diastrophic dysplasia, and has symptoms including joint stiffness, arthralgia and tremor. An important gene associated with Osteoarthritis is FRZB (Frizzled Related Protein), and among its related pathways/superpathways are Degradation of the extracellular matrix and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Prednisone and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include Cartilage and Bone, and related phenotypes are abnormality of pelvic girdle bone morphology and hip osteoarthritis

Disease Ontology : 12 An arthritis that has material basis in worn out cartilage located in joint.

MedlinePlus : 42 Osteoarthritis is the most common form of arthritis. It causes pain, swelling, and reduced motion in your joints. It can occur in any joint, but usually it affects your hands, knees, hips or spine. Osteoarthritis breaks down the cartilage in your joints. Cartilage is the slippery tissue that covers the ends of bones in a joint. Healthy cartilage absorbs the shock of movement. When you lose cartilage, your bones rub together. Over time, this rubbing can permanently damage the joint. Risk factors for osteoarthritis include Being overweight Getting older Injuring a joint There is no specific test for osteoarthritis. Most doctors use several methods, including medical history, a physical exam, x-rays, or lab tests. Treatments include exercise, medicines, and sometimes surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

CDC : 3 Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or "wear and tear" arthritis. It occurs most frequently in the hands, hips, and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work.

PubMed Health : 62 About osteoarthritis: Painful or stiff joints and a crunching sensation in the joints are typical signs of osteoarthritis, often also called "degenerative joint disease." Lots of people have joint problems as they get older, and some already have problems in middle age. If symptoms get worse, they can severely limit mobility. Osteoarthritis can affect every joint, but it is most common in the knee, hip or spine.

Wikipedia : 74 Osteoarthritis (OA) is a type of joint disease that results from breakdown of joint cartilage and... more...

Related Diseases for Osteoarthritis

Diseases related to Osteoarthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1181)
# Related Disease Score Top Affiliating Genes
1 pseudoachondroplasia 33.4 MATN3 COMP COL2A1 ACAN
2 diastrophic dysplasia 33.2 MATN3 COMP COL2A1
3 cartilage disease 33.1 COMP COL2A1 ACAN
4 otospondylomegaepiphyseal dysplasia, autosomal recessive 33.0 COMP COL2A1
5 epiphyseal dysplasia, multiple, 2 32.8 MATN3 COMP
6 epiphyseal dysplasia, multiple, 1 32.7 MATN3 COMP
7 exostosis 32.5 GDF5 COL2A1 ACAN
8 epiphyseal dysplasia, multiple, 5 32.5 MATN3 COMP
9 synovitis 32.5 COMP COL2A1 ACAN
10 rheumatoid arthritis 32.4 HOTAIR H19 COMP COL2A1 CILP ACAN
11 arthropathy 32.2 COMP COL2A1 CILP ACAN
12 back pain 32.1 CILP ASPN
13 bone disease 31.4 MATN3 GDF5 COMP COL2A1 ACAN
14 osteochondritis dissecans 31.4 MATN3 COMP COL2A1 ACAN
15 spondyloepiphyseal dysplasia with congenital joint dislocations 31.3 COMP COL2A1 ACAN
16 chondromalacia 31.3 COMP ACAN
17 degenerative disc disease 31.3 GDF5 ASPN ACAN
18 multiple epiphyseal dysplasia 31.2 MATN3 COMP COL2A1 ACAN
19 spondylolisthesis 31.1 GDF5 ACAN
20 multiple epiphyseal dysplasia, autosomal dominant 31.1 MATN3 COMP
21 spondyloepiphyseal dysplasia congenita 31.0 MATN3 COMP COL2A1
22 bone inflammation disease 31.0 COMP COL2A1 ACAN
23 achondroplasia 30.9 COMP COL2A1 ACAN
24 brachydactyly 30.8 GDF5 COMP COL2A1 ACAN
25 skeletal dysplasias 30.8 MATN3 COMP COL2A1
26 osteochondrosis 30.8 COL2A1 ACAN
27 hypochondrogenesis 30.4 MATN3 COL2A1 ASPN ACAN
28 fibrochondrogenesis 30.4 GDF5 COL2A1 ACAN
29 spondyloepimetaphyseal dysplasia, matrilin-3 related 30.4 MATN3 COMP COL2A1 ACAN
30 odontochondrodysplasia 30.3 MATN3 GDF5 COMP COL2A1 ACAN
31 clubfoot 29.8 HOTAIR GDF5 COL2A1
32 pituitary adenoma 29.6 MEG3 HOTAIR H19
33 glioma susceptibility 1 29.4 MEG3 HOTAIR H19 GAS5
34 myeloma, multiple 28.7 MEG3 HOTAIR H19 GAS5
35 osteogenic sarcoma 28.6 PACERR MEG3 HOTAIR H19 GAS5 FRZB
36 malignant glioma 28.6 PCGEM1 MEG3 HOTAIR H19 GAS5
37 multicentric osteolysis, nodulosis, and arthropathy 12.8
38 arthropathy, progressive pseudorheumatoid, of childhood 12.7
39 short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans 12.7
40 osteoarthritis with mild chondrodysplasia 12.7
41 behcet's syndrome arthropathy 12.4
42 arthropathy, erosive 12.3
43 multicentric osteolysis-nodulosis-arthropathy spectrum 12.3
44 transient arthropathy 12.3
45 loeys-dietz syndrome 3 12.3
46 czech dysplasia 12.2
47 chondrocalcinosis 2 12.1
48 myhre syndrome 12.1
49 familial osteochondritis dissecans 12.1
50 esophageal atresia 11.9

Comorbidity relations with Osteoarthritis via Phenotypic Disease Network (PDN): (show all 23)


Active Peptic Ulcer Disease Acute Cystitis
Anxiety Benign Essential Hypertension
Bronchitis Decubitus Ulcer
Deficiency Anemia Dysthymic Disorder
Esophagitis First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Major Depressive Disorder
Osteoporosis Peripheral Vascular Disease
Rheumatoid Arthritis Schizophreniform Disorder
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Osteoarthritis:



Diseases related to Osteoarthritis

Symptoms & Phenotypes for Osteoarthritis

Human phenotypes related to Osteoarthritis:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of pelvic girdle bone morphology 31 HP:0002644
2 hip osteoarthritis 31 HP:0008843

UMLS symptoms related to Osteoarthritis:


joint stiffness, arthralgia, tremor, back pain, angina pectoris, sciatica, equilibration disorder, muscle cramp, metatarsalgia, joint symptom, musculoskeletal symptom, other symptoms referable to joint, stiffness of joint, not elsewhere classified in icd10cm, other symptoms referable to joint, shoulder region, other symptoms referable to joint, upper arm, other symptoms referable to joint, forearm, other symptoms referable to joint, hand, other symptoms referable to joint, pelvic region and thigh, other symptoms referable to joint, lower leg, other symptoms referable to joint, ankle and foot, other symptoms referable to joint, other specified sites, other symptoms referable to joint, multiple sites, other symptoms referable to joint, site unspecified

Drugs & Therapeutics for Osteoarthritis

PubMed Health treatment related to Osteoarthritis: 62

There are many different suggestions and recommendations for treating osteoarthritis , but so far no cure. Most treatments aim to at least slow down the development of osteoarthritis and relieve the symptoms so that daily life is affected as little as possible. There are two different types of therapies : Surgical and non-surgical. Non-surgical therapies include painkillers, exercise and weight loss, for example. Obese people with osteoarthritis of the knee or hip are often advised to lose weight. Studies indicate that weight loss can be helpful if it is combined with exercise therapy . The question of which therapies can improve mobility and relieve pain also depends on the joint that is affected. For example, therapy involving aerobics or muscle -strengthening exercises could help people with knee osteoarthritis . Other treatment options include massage , acupuncture , TENS, medicinal baths or orthopedic insoles. Surgery options for osteoarthritis of the knee include smoothing the cartilage (arthroscopy ). But in many cases people who have had an arthroscopy to smooth out their knee cartilage experience pain and difficulties just as often as those who do not have an operation . There are other surgical therapy options available for people with advanced osteoarthritis. For example, a knee or hip joint can be replaced fully or in part with an artificial joint (called an endoprosthesis).

Drugs for Osteoarthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 611)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Azithromycin Approved Phase 4 83905-01-5 447043 55185
3
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
6
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
7
Aceclofenac Approved, Investigational Phase 4 89796-99-6
8 Orange Approved Phase 4
9
Histamine Approved, Investigational Phase 4 51-45-6 774
10
Chlorzoxazone Approved Phase 4 95-25-0 2733
11
Ibuprofen Approved Phase 4 15687-27-1 3672
12
Lumiracoxib Approved, Investigational Phase 4 220991-20-8 151166
13
Promethazine Approved, Investigational Phase 4 60-87-7 4927
14
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
15
Zolpidem Approved Phase 4 82626-48-0 5732
16
Nabumetone Approved Phase 4 42924-53-8 4409
17
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
18
Denosumab Approved Phase 4 615258-40-7
19
Enoxaparin Approved Phase 4 9005-49-6 772
20
Rivaroxaban Approved Phase 4 366789-02-8
21
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
22
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
23
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
24
Infliximab Approved Phase 4 170277-31-3
25
Prilocaine Approved Phase 4 721-50-6 4906
26
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
27
Dalteparin Approved Phase 4 9005-49-6
28
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
29
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
30
Zinc Approved, Investigational Phase 4 7440-66-6 32051
31
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
32
Hyoscyamine Approved Phase 4 101-31-5 64692
33
parecoxib Approved Phase 4 198470-84-7
34
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
35
Ticagrelor Approved Phase 4 274693-27-5 9871419
36
Rutin Approved, Experimental, Investigational Phase 4 153-18-4 5280805
37
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
38
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
39
Demeclocycline Approved Phase 4 127-33-3 5311063
40
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
41
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
42
Amlodipine Approved Phase 4 88150-42-9 2162
43
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
44
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
45
Ergotamine Approved Phase 4 113-15-5 8223
46
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
47
Propranolol Approved, Investigational Phase 4 525-66-6 4946
48
Nortriptyline Approved Phase 4 72-69-5 4543
49
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
50
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795

Interventional clinical trials:

(show top 50) (show all 4652)
# Name Status NCT ID Phase Drugs
1 Artelon MTP Spacer - Surgical Treatment of Mild to Moderate Hallux Rigidus Unknown status NCT01028469 Phase 4
2 Comparison Between Minimally Invasive Anterior Approach and Direct Lateral Approach in Total Hip Arthroplasty - A Prospective Randomized Trial Unknown status NCT01578746 Phase 4
3 Assessment of a Knee Brace in Patients With Osteoarthritis Unknown status NCT02706106 Phase 4
4 Intraarticular Xylitol Injections for Knee Osteoarthritis Unknown status NCT02104596 Phase 4
5 EVALUATION OF THE RELATIONSHIP BETWEEN EFFERVESCENT PARACETAMOL AND BLOOD PRESSURE. CLINICAL TRIAL. Unknown status NCT02514538 Phase 4 Non- effervescent Paracetamol kern;Effervescent paracetamol termalgin
6 A Multicenter,Open-label Phase Ⅳ Trial of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4 Imrecoxib
7 Effect of Flex-a-New on Osteoarthritis of the Knee Unknown status NCT00294801 Phase 4 flex-a-new (food supplement)
8 A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy of Celecoxib 200 Mg Qd in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee Unknown status NCT00194090 Phase 4 celecoxib
9 A Single-Blind Prospective Parallel Control Group Pilot Study to Assess the Effect of Hylan G-F 20 (Synvisc) Supplementation on Cartilage Preservation in Osteoarthritis of the Knee Unknown status NCT00393393 Phase 4 intra-articular injection of Hylan G-F 20
10 Prospective, Single Arm, Pilot Study Evaluating the Safety and Efficacy of Hyaluronan (Hylan GF-20) in Patients With Painful Shoulder Osteoarthritis Unknown status NCT00253799 Phase 4
11 Comparison of Single Intra-articular Injection of Hyruan-One With Hylan G-F 20 in Knee Osteoarthritis: A Randomized Double-blind, Saline-controlled Trial Unknown status NCT03484091 Phase 4 Hyruan-One;Hylan G-F 20;Normal saline
12 Randomized, Double-blind, Placebo-controlled Study to Asses the Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis by Functional Magnetic Resonance Imaging Unknown status NCT01226615 Phase 4 Chondroitin sulphate (Condrosan®);Placebo
13 A Prospective, Randomized, Double-blinded, Multi-center, Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered Orally in Patients With Knee Osteoarthritis Unknown status NCT03404479 Phase 4 Diacerein;Celecoxib
14 Double-blind, Randomised, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of the Combination of Chondroitin Sulphate and Glucosamine Hydrochloride in Patients With Hand Osteoarthritis Unknown status NCT02823548 Phase 4 Droglican;Placebo
15 Prospective Randomized Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty Unknown status NCT03359525 Phase 4 Tranexamic Acid
16 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
17 Intra-Articular Injections of Hyaluronan Versus 20 Ml NaCl Versus Placebo in Treatment of Knee Osteoarthritis: a Randomised, Double-Blind, Placebo Controlled Single Centre Trial. Unknown status NCT00144820 Phase 4 Injection of Hyaluronan or Saline
18 A Multicentre, Randomized, Double-blinded, Parallel-controlled, Non-inferiority Clinical Study Of Safety and Efficacy Of Medical Chitosan for Knee Osteoarthritis Compared With Sodium Hyaluronate Injection Unknown status NCT02323451 Phase 4 Sodium Hyaluronate Injection
19 Comparison of Therapeutic Effects of Hyaluronic Acid vs. Hyaluronic Acid Combined Corticosteroid on Knee Osteoarthritis: A Double Blind, Randomized-controlled Clinical Trial Unknown status NCT02625727 Phase 4
20 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
21 Additional Therapeutic Effects of Triamcinolone to Hyaluronic Acid on Knee Osteoarthritis: A Double Blind, Randomized-controlled Clinical Trial Unknown status NCT02949466 Phase 4 Triamcinolone
22 Influence of Perception of Patients Suffering of Osteoarthritis of Knee Over the Effectiveness and Tolerance in Intra-articular Injection of Corticoids: a Prospective, Controlled and Randomized Study Unknown status NCT02835521 Phase 4 Joint injection with triamcinolone hexacetonide
23 Additional Therapeutic Effects of Dextrose to Hyaluronic Acid on Knee Osteoarthritis: a Double Blind, Randomized-controlled Clinical Trial Unknown status NCT03238183 Phase 4 dextrose
24 Investigating the Use of a Cryopneumatic Therapy Device in Primary Total Knee Arthroplasty Patients Unknown status NCT00712816 Phase 4
25 Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex and AGC Unknown status NCT00294528 Phase 4
26 A 26 Week Multicenter Prospective Open Label Clinical Study Evaluating a Single Intra-articular Injection of DUROLANE SJ1ml for Treatment of OA Pain of the Ankle Unknown status NCT02627859 Phase 4
27 Intra-articular Botulinum Toxin Type A Versus Corticosteroids: a Clinical Trial in Osteoarthritis of Knees Unknown status NCT02829281 Phase 4 Botulinum Toxin Type A;Triamcinolone hexacetonide;Saline
28 Viscosupplementation in Patients With Severe Osteoarthritis of the Knee Unknown status NCT03090698 Phase 4 Hylan G-F 20;Triamcinolone
29 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
30 The Biomechanical Impact of Intra-Articular Hyaluronic Acid in Knee Osteoarthritis Patients: A Randomized, Double Blind, Placebo Controlled Study Unknown status NCT00778076 Phase 4
31 Effects of Perioperative Intravenous Dexamethasone on the Severity of Persistent Postsurgical Pain After Total Knee Arthroplasty : A Prospective, Randomized, Double-blind, Placebo-controlled Trial Unknown status NCT02760459 Phase 4 Dexamethasone;Normal saline solution
32 Effectiveness of Trapeziometacarpal Splint Unknown status NCT02635932 Phase 4
33 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty - Randomized Prospective Study Unknown status NCT02152917 Phase 4 Tranexamic acid;Floseal®
34 A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
35 The Effect of Glucosamine Sulphate on Structural Disease Progression in Knee Osteoarthritis and the Cost-effectiveness of Glucosamine Sulphate for Knee Arthritis. Unknown status NCT00513422 Phase 4
36 A Multi-center, Randomized, Open-label, Parallel-arm Controlled Study Comparing Demand-based Monotherapy of Non-steroidal Anti-inflammatory Drug (NSAID) vs. Demand-based NSAID Combined With Sodium Hyaluronate Injection in the Treatment of Chinese Patients With Mild to Moderate Knee Osteoarthritis Unknown status NCT02826031 Phase 4 Sodium Hyaluronate Injection;DICL-SR
37 Hip Viscosupplementation: What is the Best Dosage? Unknown status NCT01810809 Phase 4 1 ampoule of Hylan GF-20;2 ampoules of Hylan GF-20;3 ampoules of Hylan GF-20
38 Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Unknown status NCT01027819 Phase 4
39 Effect of Preoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty : A Randomized, Controlled, Double-Blind Trial Unknown status NCT03561506 Phase 4 Ferric carboxymaltose;0.9% Normal Saline
40 The Effects of Tourniquet Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
41 Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Measurement With Sensory and Quantitive Functional Tests and Concordance Analysis With Subjective Scales of Pain. Unknown status NCT01233739 Phase 4 Chondroitin sulfate;Placebo
42 Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
43 A Post-marketing Surveillance to Evaluate the Efficacy and Safety of CHONDRON (Autologous Cultured Chondrocyte) Through Arthroscopy in Patients With Knee Cartilage Defects Unknown status NCT02539069 Phase 4
44 This Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) in Patients With Cartilage Defects in Their Knees. Unknown status NCT02539056 Phase 4
45 Bone Forming at Prosthetic Surfaces. A Randomized Clinical F-PET/CT Study Unknown status NCT01623687 Phase 4
46 Outcome Comparison of Allogenic Cancellous Bone and a New Synthetic Bone Substitute (geneX®) in Filling the Bone Defect Created With Medial Open Wedge High Tibial Osteotomy Unknown status NCT02000297 Phase 4
47 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4 Sodium hyaluronate (hyaluronic acid)
48 Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN: a Pilot Study Unknown status NCT02821468 Phase 4 Droglican;Paracetamol or oral NSAIDs excluding COX2 inhibitors
49 A Randomized Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery. Influence on Operative Result, Health-Related Quality of Life, and Coordinative Abilities. Unknown status NCT00431509 Phase 4
50 Effect of Postoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty : A Randomized, Controlled, Double-Blind Trial Unknown status NCT03561480 Phase 4 Ferric carboxymaltose;0.9% Normal Saline

Search NIH Clinical Center for Osteoarthritis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ACETYLSALICYLATE SODIUM
Aspirin
ASPIRIN PWDR
celecoxib
choline salicylate
Chondroitin
CHONDROITIN SODIUM
Chondroitin Sulfates
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Diflunisal
Etodolac
Fenoprofen
Fenoprofen Calcium
Flurbiprofen
Flurbiprofen sodium
Glucosamine
HYLAN G-F 20
Ibuprofen
Indomethacin
INDOMETHACIN PWDR
INDOMETHACIN SODIUM
Ketoprofen
KETOPROFEN PWDR
meloxicam
nabumetone
Naproxen
Naproxen sodium
oxaprozin
Piroxicam
rofecoxib
solufenum
Sulindac
Tolmetin
Tolmetin Sodium
valdecoxib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteoarthritis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteoarthritis:
4D20.8 PureStem-derived chondrocytes for treatment of osteochondral defects
AlloStem, adipose-derived mesenchymal stem cells combined with allograft bone for bone grafting
Autologous adipose-derived mesenchymal stromal cells for the treatment of osteoarthritis
Autologous bone marrow-derived stem cells for the treatment of osteoarthritis
Autologous chondrocyte for severe hip osteoarthritis
Bone marrow-derived mesenchymal stem cells for osteoarthritis
Bone marrow-derived mesenchymal stem cells for knee osteoarthritis
Bone marrow-derived mesenchymal stem cells for knee osteoarthritis
Bone marrow-derived stem cells for knee osteoarthritis
Carticel, autologous cultured chondrocytes for treatment of cartilage defects
CARTISTEM, mesenchymal stem cells for treatment of osteoarthritis
Chondrocell, bone marrow-derived mesenchymal stem cells for osteoarthritis
Chondrogen, mesenchymal stem cells for meniscus regeneration and knee osteoarthritis prevention
HiQCell, adipose-derived stromal vascular fraction for osteoarthritis
JACC, cultured cartilage for chondral lesion
Mesenchymal stem cell for meniscal regeneration after hemi-meniscectomy
ReJoin(TM), adipose-derived mesenchymal precursor cell for knee osteoarthritis
RNL-JointStem, adipose-derived mesenchymal stem cells for degenerative arthritis
StempeucelOA, mesenchymal stem cells for treatment of osteoarthritis
Trinity Evolution, mesenchymal stem cells with osteoprogenitors for musculoskeletal defects
Embryonic/Adult Cultured Cells Related to Osteoarthritis:
PureStem 4D20.8, NCr-fac Progenitor PMIDs: 22519755
Adipose-derived mesenchymal stem cells combined with allograft bone (AlloStem) PMIDs: 22500696
Adipose-derived mesenchymal stromal cells PMIDs: 23613363
Bone marrow-derived mesenchymal stem cells
Bone marrow-derived mesenchymal stromal cells
Chondrocytes (Carticel) PMIDs: 17515233 17590152 16510814
Bone marrow-derived mesenchymal stem cells (family)
Bone marrow-derived mesenchymal stem cells PMIDs: 12708651 19530993 14673997 10102814
Adipose-derived stromal vascular fraction and adipocytes (HiQCell) PMIDs: 22913454
Cultured cartilage (JACC) PMIDs: 19393556 10738867 16226641 12043781 16233853 19802670 10679677 11284883 16233778
Bone marrow-derived mesenchymal stem cells PMIDs: 22750747
Bone marrow-derived mesenchymal stem cells PMIDs: 22750747
Adipose-derived mesenchymal stem cells (family)
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 22837175
Demineralized bone with osteoprogenitor and adult stem cells (Trinity Evolution) PMIDs: 20508015 21056860

Genetic Tests for Osteoarthritis

Genetic tests related to Osteoarthritis:

# Genetic test Affiliating Genes
1 Osteoarthritis 29 FRZB

Anatomical Context for Osteoarthritis

The Foundational Model of Anatomy Ontology organs/tissues related to Osteoarthritis:

19
Joint

MalaCards organs/tissues related to Osteoarthritis:

40
Bone, Testes, Bone Marrow, Brain, Endothelial, Skin, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Osteoarthritis:
# Tissue Anatomical CompartmentCell Relevance
1 Cartilage Temporomandibular Joint Affected by disease
2 Bone Vertebrae Affected by disease
3 Cartilage Autopod Articular Cartilage Articular Cartilage Cells Affected by disease
4 Cartilage Zeugopod Articular Cartilage Articular Cartilage Cells Affected by disease
5 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
6 Limb Zeugopod Synovial Joint Central Intermediate Lamina Cells Affected by disease
7 Limb Autopod Synovial Joint Central Intermediate Lamina Cells Affected by disease
8 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
9 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Osteoarthritis

Articles related to Osteoarthritis:

(show top 50) (show all 33751)
# Title Authors PMID Year
1
Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. 6 61
15210948 2004
2
Acupuncture and moxibustion for pain relief and quality of life improvement in patients with knee osteoarthritis: A protocol for systematic review and meta-analysis. 61 42
32481382 2020
3
Minimally Invasive Total Knee Arthroplasty: Does Surgical Technique Actually Impact the Outcome? 42
32498949 2020
4
Can isolated removal of osteophytes achieve correction of varus deformity and gap-balance in computer-assisted total knee arthroplasty? 42
32475289 2020
5
Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development. 61 54
20495570 2010
6
A COL2A1 gene polymorphism is related with advanced stages of osteoarthritis of the knee in Mexican Mestizo population. 54 61
19756630 2010
7
Serum transforming growth factor-beta 1 is not a robust biomarker of incident and progressive radiographic osteoarthritis at the hip and knee: the Johnston County Osteoarthritis Project. 54 61
20206313 2010
8
Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants. 54 61
19902332 2010
9
MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. 61 54
20131257 2010
10
A meta-analysis of interleukin-6 promoter polymorphisms on risk of hip and knee osteoarthritis. 61 54
20175976 2010
11
Interleukin-1 gene cluster variants with innate cytokine production profiles and osteoarthritis in subjects from the Genetics, Osteoarthritis and Progression Study. 54 61
20131253 2010
12
Changes in content and synthesis of collagen types and proteoglycans in osteoarthritis of the knee joint and comparison of quantitative analysis with Photoshop-based image analysis. 54 61
19838720 2010
13
[Expressions of interleukin 18 and prostaglandin E2 and their correlation in the synoviocytes of patients with osteoarthritis]. 61 54
20423837 2010
14
High specificity but low sensitivity of the cartilage oligomeric matrix protein (COMP) test in rheumatoid arthritis and osteoarthritis. 54 61
20148721 2010
15
Hyaluronic acid modulates gene expression of connective tissue growth factor (CTGF), transforming growth factor-beta1 (TGF-beta1), and vascular endothelial growth factor (VEGF) in human fibroblast-like synovial cells from advanced-stage osteoarthritis in vitro. 61 54
19890996 2010
16
A matrilin-3 mutation associated with osteoarthritis does not affect collagen affinity but promotes the formation of wider cartilage collagen fibrils. 61 54
20077500 2010
17
The genetic epidemiology of osteoarthritis. 61 54
20090528 2010
18
Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. 54 61
20112374 2010
19
[Detection of bone erosions in knee osteoarthrosis by serum biomarkers]. 54 61
20422912 2010
20
The transcript level of interleukin-6 in the cartilage of idiopathic osteoarthritis of knee. 61 54
20393674 2010
21
Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical training. 61 54
19679221 2010
22
Modulating hedgehog signaling can attenuate the severity of osteoarthritis. 54 61
19915594 2009
23
Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. 61 54
19762475 2009
24
Association of a functional microsatellite within intron 1 of the BMP5 gene with susceptibility to osteoarthritis. 61 54
20021689 2009
25
Association of the DVWA and GDF5 polymorphisms with osteoarthritis in UK populations. 61 54
19054821 2009
26
Genetic variation in the GDF5 region is associated with osteoarthritis, height, hip axis length and fracture risk: the Rotterdam study. 54 61
19029166 2009
27
Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation. 54 61
19877068 2009
28
Asporin and transforming growth factor-beta gene expression in osteoblasts from subchondral bone and osteophytes in osteoarthritis. 54 61
19997821 2009
29
COL2A1 gene polymorphisms and susceptibility to osteoarthritis of the hand in Finnish women. 54 61
19019890 2009
30
Elevated circulating and synovial fluid endoglin are associated with primary knee osteoarthritis severity. 54 61
20082874 2009
31
Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. 54 61
19684582 2009
32
Expression and activity of COX-1 and 2 and 5-LOX in joint tissues from dogs with naturally occurring coxofemoral joint osteoarthritis. 54 61
19274754 2009
33
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. 61 54
19606871 2009
34
Phellodendron and Citrus extracts benefit joint health in osteoarthritis patients: a pilot, double-blind, placebo-controlled study. 54 61
19682376 2009
35
Missense single nucleotide polymorphism of the ADAM12 gene is associated with radiographic knee osteoarthritis in middle-aged Estonian cohort. 61 54
19268722 2009
36
Selective MMP-12 inhibitors: WO-2008057254. 54 61
19456279 2009
37
[Effect of electroacupuncture on the level of IL-1beta and TNF-alpha in patients with osteoarthritis]. 54 61
19835118 2009
38
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. 61 54
19565489 2009
39
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. 61 54
19602530 2009
40
Global analysis of nuclear receptor expression and dysregulation in human osteoarthritic articular cartilage: reduced LXR signaling contributes to catabolic metabolism typical of osteoarthritis. 61 54
19217805 2009
41
The knee osteoarthritis susceptibility locus DVWA on chromosome 3p24.3 is the 5' part of the split COL6A4 gene. 54 61
19486942 2009
42
Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. 54 61
19565481 2009
43
Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease. 54 61
19366851 2009
44
Fibroblast growth factor 2: A new key player in osteoarthritis. 61 54
19565484 2009
45
Functional analysis of the osteoarthritis susceptibility-associated GDF5 regulatory polymorphism. 61 54
19565498 2009
46
Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. 61 54
19479880 2009
47
Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. 61 54
19494318 2009
48
[Genomic study of susceptibility genes for common bone and joint diseases]. 61 54
19507504 2009
49
Failure of serum transforming growth factor-beta (TGF-beta1) as a biomarker of radiographic osteoarthritis at the knee and hip: a cross-sectional analysis in the Johnston County Osteoarthritis Project. 54 61
19091605 2009
50
Differential upregulation of the three transforming growth factor beta isoforms in human osteoarthritic cartilage. 61 54
18467513 2009